Investing.com – Belgium equities were higher at the close on Tuesday, as gains in the Consumer Goods, Consumer Services and Healthcare sectors propelled shares higher. At the...
Investing.com – Belgium equities were lower at the close on Monday, as losses in the Telecoms, Consumer Services and Industrials sectors propelled shares lower. At the close in...
Investing.com – Belgium equities were higher at the close on Friday, as gains in the Consumer Goods, Healthcare and Technology sectors propelled shares higher. At the close in...
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Sell | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 487.40 | 490.40 | 483.00 | +4.00 | +0.83% | 1.78M | London | |||
| 1,946.90 | 1,959.80 | 1,930.70 | +7.9 | +0.41% | 36.05K | London | |||
| 217.40 | 220.00 | 214.60 | +2.15 | +1.00% | 1.09M | London | |||
| 24.20 | 24.20 | 24.20 | +0.70 | +3.00% | 4.53M | London | |||
| 4,636.50 | 4,761.50 | 4,612.00 | -84.5 | -1.79% | 821.89K | London | |||
| 999.34 | 1,001.40 | 988.80 | +13.50 | +1.37% | 2.10M | London | |||
| 33.00 | 35.50 | 35.50 | -3.00 | -8.33% | 2.18M | London | |||
| 217.00 | 221.30 | 215.50 | -0.30 | -0.14% | 5.57M | London | |||
| 1,700.00 | 1,702.00 | 1,700.00 | 0.00 | 0.00% | 0.00 | London | |||
| 163.38 | 165.00 | 159.70 | +2.45 | +1.52% | 3.61M | London | |||
| 258.00 | 258.00 | 258.00 | -5.00 | -1.96% | 23.51K | London | |||
| 2.13 | 2.14 | 2.00 | +0.08 | +3.90% | 2.40M | London | |||
| 192.70 | 192.90 | 189.60 | +3.20 | +1.69% | 3.12M | London | |||
| 186.40 | 189.80 | 184.84 | -0.84 | -0.45% | 5.70M | London | |||
| 5,752.00 | 5,764.00 | 5,674.50 | +110.0 | +1.95% | 59.45K | London |